(Q83339318)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Jantunen E

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Itälä M

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Siitonen T

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Juvonen E

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Koivunen E

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Koistinen P

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Remes K

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Nousiainen T

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

8 May 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

21 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

1093-1098

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16699533%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705375

21 January 2020

exact match

0 references

cites work

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Stem cell transplantation for chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leuk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

CD34+-enriched–CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of UnmutatedVHGene in Patients With Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021

Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705375

7 January 2021